New breast cancer radiotherapy technology launches in Europe

John E. Kaye
- Published
- Technology

An “extraordinary” new technology promising to transform the treatment of early-stage breast cancer has arrived in Europe
GammaPod, a system designed to deliver high-dose, targeted radiotherapy in a single session, has been introduced by Tema Sinergie SpA, an Italian healthcare company based in Faenza.
The first European installation of GammaPod has been completed at the Santa Maria della Misericordia Hospital in Udine, with additional sites expected to begin treating patients soon. Tema Sinergie, which has over 40 years of experience in the healthcare sector, is working to expand access to the technology across the continent.
Invented by physicist Cedric Yu, Professor Emeritus at the University of Maryland in the United States, and produced by Xcision Medical Systems — the company Yu founded — GammaPod is the first radiotherapy system created specifically to treat breast cancer. Unlike conventional radiotherapy equipment, which is designed for use across different parts of the body, GammaPod focuses solely on breast tumours. This allows it to deliver concentrated doses of radiation directly to the tumour while sparing surrounding healthy tissue and reducing side effects.
Because the treatment is so precisely targeted, GammaPod enables the tumour to be treated with a much higher dose of radiation than conventional methods, and crucially, in a single session rather than multiple treatments. The non-invasive approach is designed to shorten the course of therapy, with potential benefits for patients’ quality of life.
A clinical study conducted at the Udine hospital, recently published in the International Journal of Radiation Oncology, Biology, Physics (commonly known as the Red Journal), demonstrated that GammaPod is both safe and effective when used in pre-operative treatment. The study showed a significant reduction in Ki-67, a marker used to assess how actively cancer cells are proliferating, indicating a strong tumour response to the radiation.
“The results are extraordinary,” Dr Marco Trovò, Director of Radiotherapy at Santa Maria della Misericordia Hospital, said. “GammaPod allows us to administer a very high dose of radiation in a single session, with a clear biological response, as indicated by the drop in Ki-67.”

GammaPod will also be showcased at the upcoming ESTRO 2025 congress in Vienna. During the congress, Tema Sinergie will host a Satellite Symposium on 5 May titled “Reducing the Impact of Breast Cancer”. The session will include presentations by Prof Cedric Yu, Prof Asal Rahimi, and Dr Marco Trovò, who will discuss clinical results and the technology’s application. Moderators for the session will be Prof Philip Poortmans and Prof Icro Meattini.
Tema Sinergie’s role in introducing GammaPod to Europe highlights the importance of international collaboration in advancing cancer treatment options. The company said it is committed to ensuring that the technology becomes a key part of breast cancer care in Europe and beyond.
Photos: GammaPod
Sign up to The European Newsletter
RECENT ARTICLES
-
Speed-driven email security: effective tactics for phishing mitigation
-
Short circuit: humanoids go for gold at first 'Olympics for robots'
-
New IBM–NASA AI aims to forecast solar flares before they knock out satellites or endanger astronauts
-
AI is powering the most convincing scams you've ever seen
-
British firm Skyral to help Mongolia tackle pollution with AI traffic modelling
-
The nuclear medicine breakthrough transforming cancer care
-
Second to none: the watchmaker who redefined time for women
-
How AI agents are supercharging cybercrime
-
The CEO making culture the driving force for innovation
-
Penelope J. Corfield on the secret gestures that shape society
-
In Africa, hepatitis B is a silent killer. And a $1 test could stop it
-
'Our real rivals are TikTok and Netflix’ – iGaming firm Soft2Bet sets out strategy for global expansion
-
AI agents are just the start. Here’s what comes next
-
Why cybersecurity deserves a place in the political spotlight
-
Outpacing cyber threats, winning the race
-
Who is really cutting emissions? These satellites will tell us
-
New Science Matters supplement out now — Europe’s boldest ideas in one place
-
New app reveals hidden health risks in everyday foods
-
Alzheimer’s vaccine enters human trials aiming to stop disease before symptoms begin
-
US researchers develop storm-resistant drone to improve extreme weather forecasting
-
Robot folds 800 napkins in 24 hours as Dyna Robotics launches first commercial-ready embodied AI
-
New breast cancer radiotherapy technology launches in Europe
-
Blockchain boom could create over 1 million jobs by 2030, new report claims
-
Why modern computer games aren’t a patch on the classics
-
Watch: Robotic bellboys checking in to a hotel near you soon